SEQUENCE LISTING

<110> Smythe , Mark Leslie
       Meutermans, Wim Denis Franss

<120> Auxiliary for Amide Bond Formation

<130> 4050.001100

<140> 09/787,840
<141> 2001-07-06

<150> PCT/AU99/00812
<151> 1999-09-24

<150> AU PP6165
<151> 1998-09-25

<160> 43

<170> PatentIn version 3.2

<210> 1
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HS-(CH2)2-Tyr

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Gly-OH

<400> 1

Xaa Arg Phe Xaa
1

<210> 2
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = butyl-Tyr substituted

<220>
<221> MISC_FEATURE

```
<222>  (2)..(2)
<223>  Xaa = 2,2,5,7,8-pentamethylchroman-6-sulfonyl-Arg

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Gly WANG resin

<400>  2

Xaa Xaa Phe Xaa
1


<210>  3
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(5-nitro-2-mercaptobenzyl)-Tyr

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Gly-OH

<400>  3

Xaa Arg Phe Xaa
1


<210>  4
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = HS-(CH2)2-Ala

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = Ala-OH

<400>  4

Xaa Phe Leu Pro Xaa
1               5
```

```
<210>  5
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = Ala-WANG resin

<400>  5

Ala Phe Leu Pro Xaa
1               5


<210>  6
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = HS-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Ala-OH

<400>  6

Xaa Leu Pro Xaa
1


<210>  7
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-5-nitrobenzyl)-Ala

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
```

<223> Xaa = Ala-OH

<400> 7

Xaa Phe Leu Pro Xaa
1   5

<210> 8
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa a= N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Ala-OH

<400> 8

Xaa Phe Leu Pro Xaa
1   5

<210> 9
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 9

Val Ala Gly Phe
1

<210> 10
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 10

Ala Phe Leu Pro Ala
1   5

<210> 11
<211> 5

```
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400>  11

Xaa Leu Pro Ala Ala
1                   5


<210>  12
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = S-(CH2)2-Ala

<400>  12

Xaa Phe Leu Pro Ala
1                   5


<210>  13
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = HS-(CH2)2-Ala

<400>  13

Xaa Phe Leu Pro Ala
1                   5


<210>  14
<211>  8
<212>  PRT
<213>  ARTIFICIAL
```

```
<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Ala-NH2

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Ala-OH

<400>  14

Xaa Leu Pro Xaa Xaa Leu Pro Xaa
1               5


<210>  15
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400>  15

Xaa Phe Leu Pro Ala
1               5


<210>  16
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala
```

<400> 16

Xaa Phe Leu Pro Ala
1   5

<210> 17
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 17

Xaa Leu Pro Ala Ala
1   5

<210> 18
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 18

Xaa Leu Pro Ala Ala
1   5

<210> 19
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 19

Ala Phe Leu Pro Ala
1   5

<210> 20
<211> 5

<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 20

Phe Leu Pro Ala Ala
1   5

<210> 21
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 21

Tyr Arg Phe Gly
1

<210> 22
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 22

Xaa Arg Phe Gly
1

<210> 23
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 23

Xaa Arg Phe Gly

1

<210> 24
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 24

Tyr Arg Phe Gly
1

<210> 25
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 25

Leu Tyr Arg Ala Gly
1   5

<210> 26
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 26

Gly Ala Gly Pro Ala
1   5

<210> 27
<211> 10
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 27

Leu Tyr Arg Ala Gly Gly Ala Gly Pro Ala
1   5   10

<210> 28
<211> 5
<212> PRT
<213> ARTIFICIAL

```
<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  28

Leu Tyr Arg Ala Phe
1               5


<210>  29
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  29

Ala Ala Arg His Thr
1               5


<210>  30
<211>  10
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  30

Leu Tyr Arg Ala Phe Ala Ala Arg His Thr
1               5                   10


<210>  31
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  31

Phe Leu Pro Ala Ala
1               5


<210>  32
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE

<400>  32

Phe Phe Phe Phe
```

1

<210> 33
<211> 14
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 33

Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser
1   5   10

<210> 34
<211> 16
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 34

Cys Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser Gly
1   5   10   15

<210> 35
<211> 11
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 35

Val Ser Ile Leu Glu Thr Lys Ile Tyr Gly Thr
1   5   10

<210> 36
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Ala-Trityl resin

<400> 36

Ala Phe Leu Pro Xaa
1   5

<210> 37
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Phe-resin

<400> 37

Val Ala Gly Xaa
1

<210> 38
<211> 11
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 38

Thr Gly Tyr Ile Lys Thr Glu Leu Ile Ser Val
1   5   10

<210> 39
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = H-Ala

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Ala-OH

<400> 39

Xaa Phe Leu Pro Xaa
1   5

<210> 40
<211> 8

```
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Ala-NH2

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Ala-NH2

<400>  40

Xaa Leu Pro Xaa Xaa Leu Pro Xaa
1                   5


<210>  41
<211>  8
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Ala-OH

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = S-(CH2)2-NH-CH(CH3)-CO-Phe

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Ala-OH

<400>  41
```

```
Xaa Leu Pro Xaa Xaa Leu Pro Xaa
1               5
```

```
<210>   42
<211>   5
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400>   42
```

```
Xaa Phe Leu Pro Ala
1               5
```

```
<210>   43
<211>   5
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400>   43
```

```
Xaa Phe Leu Pro Ala
1               5
```